The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Adcetris® (brentuximab vedotin) has been approved by the European Commission for CD30-positive CTCL 

Jan 22, 2018

It was announced in a press release on 22 ndJanuary 2018, that the European Commission has approved Adcetris ®(brentuximab vedotin) for the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) in adults after at least one prior systemic therapy. 

The European Medicines Agency ( EMA) Committee for Medicinal Products for Human Use ( CHMP) adopted a positive opinionfor this indication in November 2017. This followed resultsfrom the ALCANZAtrial in which brentuximab vedotin demonstrated significantly superior clinical outcomes in patients with CD30-expressing CTCL versus physician's choice

Your opinion matters

At this year’s virtual ESH Meeting, the Lymphoma Hub Satellite Symposium will evaluate treatment options in patients with R/R DLBCL. What do you think is the most promising emerging therapy in this setting?
4 vote s - 17 hours left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month